Literature DB >> 12490959

Inflammation and cancer.

Lisa M Coussens1, Zena Werb.   

Abstract

Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490959      PMCID: PMC2803035          DOI: 10.1038/nature01322

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  74 in total

Review 1.  The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues.

Authors:  P Allavena; A Sica; A Vecchi; M Locati; S Sozzani; A Mantovani
Journal:  Immunol Rev       Date:  2000-10       Impact factor: 12.988

2.  Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer.

Authors:  J Kleeff; T Kusama; D L Rossi; T Ishiwata; H Maruyama; H Friess; M W Büchler; A Zlotnik; M Korc
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

3.  L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis.

Authors:  F Qian; D Hanahan; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Tumor-associated macrophages as targets for cancer therapy.

Authors:  L M Wahl; H K Kleinman
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

5.  Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.

Authors:  L A García-Rodríguez; C Huerta-Alvarez
Journal:  Epidemiology       Date:  2001-01       Impact factor: 4.822

Review 6.  Chronic inflammation and cancer.

Authors:  Emily Shacter; Sigmund A Weitzman
Journal:  Oncology (Williston Park)       Date:  2002-02       Impact factor: 2.990

Review 7.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

Review 8.  Nitric oxide and oxygen radicals in infection, inflammation, and cancer.

Authors:  H Maeda; T Akaike
Journal:  Biochemistry (Mosc)       Date:  1998-07       Impact factor: 2.487

9.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

Authors:  D J Elder; D E Halton; A Hague; C Paraskeva
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

10.  In vivo regulation of macrophage IL-12 production during type 1 and type 2 cytokine-mediated granuloma formation.

Authors:  S W Chensue; J H Ruth; K Warmington; P Lincoln; S L Kunkel
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

View more
  2000 in total

1.  Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells.

Authors:  Chun-Te Wu; Ching-Chuan Hsieh; Cheng-Chia Lin; Wen-Cheng Chen; Ji-Hong Hong; Miao-Fen Chen
Journal:  J Mol Med (Berl)       Date:  2012-06-03       Impact factor: 4.599

2.  Epimorphin deletion protects mice from inflammation-induced colon carcinogenesis and alters stem cell niche myofibroblast secretion.

Authors:  Anisa Shaker; Elzbieta A Swietlicki; Lihua Wang; Shujun Jiang; Birce Onal; Shashi Bala; Katherine DeSchryver; Rodney Newberry; Marc S Levin; Deborah C Rubin
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

3.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

4.  Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling.

Authors:  Aaron J Grossberg; Elisabeth G Vichaya; Diana L Christian; Jessica M Molkentine; Daniel W Vermeer; Phillip S Gross; Paola D Vermeer; John H Lee; Robert Dantzer
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

5.  Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial.

Authors:  Suzanne G Orchard; Jessica E Lockery; Peter Gibbs; Galina Polekhina; Rory Wolfe; John Zalcberg; Andrew Haydon; John J McNeil; Mark R Nelson; Christopher M Reid; Brenda Kirpach; Anne M Murray; Robyn L Woods
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

6.  DCAF1 regulates Treg senescence via the ROS axis during immunological aging.

Authors:  Zengli Guo; Gang Wang; Bing Wu; Wei-Chun Chou; Liang Cheng; Chenlin Zhou; Jitong Lou; Di Wu; Lishan Su; Junnian Zheng; Jenny P-Y Ting; Yisong Y Wan
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 7.  The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms.

Authors:  Julienne E Bower
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

8.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

9.  Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.

Authors:  Wanying Zhang; Haonan Li; Hua Dong; Jie Liao; Bruce D Hammock; Guang-Yu Yang
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

10.  Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China.

Authors:  Min Shen; Roel Vermeulen; Preetha Rajaraman; Idan Menashe; Xingzhou He; Robert S Chapman; Meredith Yeager; Gilles Thomas; Laurie Burdett; Amy Hutchinson; Jeff Yuenger; Stephen Chanock; Qing Lan
Journal:  Environ Mol Mutagen       Date:  2009-05       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.